Previous 10 | Next 10 |
home / stock / brrgf / brrgf news
BERGEN, Norway , Aug. 10, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, will be announcing its results for the second quarter 2020 on Tuesday 18 August 2020 . A webcast...
BERGEN, Norway , July 7, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson , Medical Director at BerGenBio, will be participating at ...
BERGEN, Norway , June 24, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces a change to the presentation time of the Company's oral virtual presentation at ...
BERGEN, Norway , June 2, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced in the UK Government-backed Phase II clinical tria...
BERGEN, Norway , June 2, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced in the UK Government-backed Phase II clinical tria...
BERGEN, Norway , May 19, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces its results for the first quarter 2020. A live webcast presentation by the Company's m...
BERGEN, Norway , May 13, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), will announce its results for the first quarter 2020 on Tuesday 19 May 2020 . A webcast presentation by BerGenBio's senior management team will take place at 10 am CET . The presentation will webcast live a...
BERGEN, Norway , May 5, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised NOK500m (gross) (€45.4 million) via an over...
BERGEN, Norway , April 28, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that bemcentinib has been selected as the first potential treatment to be fast-tr...
BERGEN, Norway , Jan. 29, 2020 /PRNewswire/ -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA OR ...
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...